#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6. HIF and Vascular Diseases
1-1	0-2	6.	_	_	_	_
1-2	3-6	HIF	abstract|abstract[2]	new|new[2]	coref|coref	3-5|7-1[50_2]
1-3	7-10	and	abstract[2]	new[2]	_	_
1-4	11-19	Vascular	abstract[2]|abstract[3]	new[2]|new[3]	coref	3-12[14_3]
1-5	20-28	Diseases	abstract[2]|abstract[3]	new[2]|new[3]	_	_

#Text=In vascular pathology , hypoxia is typically the consequence of altered , destroyed or absent blood vessels leading to tissue ischemia .
2-1	29-31	In	_	_	_	_
2-2	32-40	vascular	abstract[4]	new[4]	_	_
2-3	41-50	pathology	abstract[4]	new[4]	_	_
2-4	51-52	,	_	_	_	_
2-5	53-60	hypoxia	abstract	new	coref	2-7[6_0]
2-6	61-63	is	_	_	_	_
2-7	64-73	typically	abstract[6]	giv[6]	coref	4-7[0_6]
2-8	74-77	the	abstract[6]	giv[6]	_	_
2-9	78-89	consequence	abstract[6]	giv[6]	_	_
2-10	90-92	of	abstract[6]	giv[6]	_	_
2-11	93-100	altered	abstract[6]|object[8]	giv[6]|new[8]	_	_
2-12	101-102	,	abstract[6]|object[8]	giv[6]|new[8]	_	_
2-13	103-112	destroyed	abstract[6]|object[8]	giv[6]|new[8]	_	_
2-14	113-115	or	abstract[6]|object[8]	giv[6]|new[8]	_	_
2-15	116-122	absent	abstract[6]|object[8]	giv[6]|new[8]	_	_
2-16	123-128	blood	abstract[6]|substance|object[8]	giv[6]|new|new[8]	coref	22-23
2-17	129-136	vessels	abstract[6]|object[8]	giv[6]|new[8]	_	_
2-18	137-144	leading	abstract[6]|object[8]	giv[6]|new[8]	_	_
2-19	145-147	to	abstract[6]|object[8]	giv[6]|new[8]	_	_
2-20	148-154	tissue	abstract[6]|object[8]|substance|abstract[10]	giv[6]|new[8]|new|new[10]	coref|coref	4-2|4-2[26_10]
2-21	155-163	ischemia	abstract[6]|object[8]|abstract[10]	giv[6]|new[8]|new[10]	_	_
2-22	164-165	.	_	_	_	_

#Text=The mechanisms of the HIF response have therefore been studied in ischemic vascular diseases , such as myocardial infarction ( consequence of obstruction of coronary arteries ) or peripheral vascular disease ( PAD , consequence of obstruction of arteries going to the limbs ) .
3-1	166-169	The	abstract[11]	new[11]	_	_
3-2	170-180	mechanisms	abstract[11]	new[11]	_	_
3-3	181-183	of	abstract[11]	new[11]	_	_
3-4	184-187	the	abstract[11]|event[13]	new[11]|new[13]	coref	5-19[41_13]
3-5	188-191	HIF	abstract[11]|abstract|event[13]	new[11]|giv|new[13]	coref	5-7
3-6	192-200	response	abstract[11]|event[13]	new[11]|new[13]	_	_
3-7	201-205	have	_	_	_	_
3-8	206-215	therefore	_	_	_	_
3-9	216-220	been	_	_	_	_
3-10	221-228	studied	_	_	_	_
3-11	229-231	in	_	_	_	_
3-12	232-240	ischemic	abstract[14]	giv[14]	coref	4-21[33_14]
3-13	241-249	vascular	abstract[14]	giv[14]	_	_
3-14	250-258	diseases	abstract[14]	giv[14]	_	_
3-15	259-260	,	abstract[14]	giv[14]	_	_
3-16	261-265	such	abstract[14]	giv[14]	_	_
3-17	266-268	as	abstract[14]	giv[14]	_	_
3-18	269-279	myocardial	abstract[14]|event[15]	giv[14]|new[15]	_	_
3-19	280-290	infarction	abstract[14]|event[15]	giv[14]|new[15]	_	_
3-20	291-292	(	_	_	_	_
3-21	293-304	consequence	abstract[16]	new[16]	_	_
3-22	305-307	of	abstract[16]	new[16]	_	_
3-23	308-319	obstruction	abstract[16]|object[17]	new[16]|new[17]	_	_
3-24	320-322	of	abstract[16]|object[17]	new[16]|new[17]	_	_
3-25	323-331	coronary	abstract[16]|object[17]|object[18]	new[16]|new[17]|new[18]	coref	3-39[23_18]
3-26	332-340	arteries	abstract[16]|object[17]|object[18]	new[16]|new[17]|new[18]	_	_
3-27	341-342	)	_	_	_	_
3-28	343-345	or	_	_	_	_
3-29	346-356	peripheral	abstract[19]	new[19]	appos	3-35[21_19]
3-30	357-365	vascular	abstract[19]	new[19]	_	_
3-31	366-373	disease	abstract[19]	new[19]	_	_
3-32	374-375	(	_	_	_	_
3-33	376-379	PAD	abstract	new	_	_
3-34	380-381	,	_	_	_	_
3-35	382-393	consequence	abstract[21]	giv[21]	coref	11-27[79_21]
3-36	394-396	of	abstract[21]	giv[21]	_	_
3-37	397-408	obstruction	abstract[21]|object[22]	giv[21]|new[22]	_	_
3-38	409-411	of	abstract[21]|object[22]	giv[21]|new[22]	_	_
3-39	412-420	arteries	abstract[21]|object[22]|object[23]	giv[21]|new[22]|giv[23]	coref	15-9[104_23]
3-40	421-426	going	abstract[21]|object[22]|object[23]	giv[21]|new[22]|giv[23]	_	_
3-41	427-429	to	abstract[21]|object[22]|object[23]	giv[21]|new[22]|giv[23]	_	_
3-42	430-433	the	abstract[21]|object[22]|object[23]|object[24]	giv[21]|new[22]|giv[23]|new[24]	_	_
3-43	434-439	limbs	abstract[21]|object[22]|object[23]|object[24]	giv[21]|new[22]|giv[23]|new[24]	_	_
3-44	440-441	)	_	_	_	_
3-45	442-443	.	_	_	_	_

#Text=Besides tissue ischemia , mechanisms of hypoxia and ischemia can occur within the vascular wall itself , with implications for diseases such as atherosclerosis , arterial aneurysm , chronic venous insufficiency and thromboembolism .
4-1	444-451	Besides	_	_	_	_
4-2	452-458	tissue	substance|abstract[26]	giv|giv[26]	coref|coref	4-9[0_26]|15-7[103_0]
4-3	459-467	ischemia	abstract[26]	giv[26]	_	_
4-4	468-469	,	_	_	_	_
4-5	470-480	mechanisms	abstract[27]	new[27]	_	_
4-6	481-483	of	abstract[27]	new[27]	_	_
4-7	484-491	hypoxia	abstract[27]|abstract	new[27]|giv	coref	11-1
4-8	492-495	and	abstract[27]	new[27]	_	_
4-9	496-504	ischemia	abstract[27]|abstract	new[27]|giv	ana	4-16
4-10	505-508	can	_	_	_	_
4-11	509-514	occur	_	_	_	_
4-12	515-521	within	_	_	_	_
4-13	522-525	the	object[30]	new[30]	coref	5-22[42_30]
4-14	526-534	vascular	object[30]	new[30]	_	_
4-15	535-539	wall	object[30]	new[30]	_	_
4-16	540-546	itself	object[30]|abstract	new[30]|giv	_	_
4-17	547-548	,	_	_	_	_
4-18	549-553	with	_	_	_	_
4-19	554-566	implications	abstract[32]	new[32]	_	_
4-20	567-570	for	abstract[32]	new[32]	_	_
4-21	571-579	diseases	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
4-22	580-584	such	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
4-23	585-587	as	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
4-24	588-603	atherosclerosis	abstract[32]|abstract[33]|abstract	new[32]|giv[33]|new	coref	7-3
4-25	604-605	,	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
4-26	606-614	arterial	abstract[32]|abstract[33]|abstract[35]	new[32]|giv[33]|new[35]	_	_
4-27	615-623	aneurysm	abstract[32]|abstract[33]|abstract[35]	new[32]|giv[33]|new[35]	_	_
4-28	624-625	,	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
4-29	626-633	chronic	abstract[32]|abstract[33]|event[36]	new[32]|giv[33]|new[36]	_	_
4-30	634-640	venous	abstract[32]|abstract[33]|event[36]	new[32]|giv[33]|new[36]	_	_
4-31	641-654	insufficiency	abstract[32]|abstract[33]|event[36]	new[32]|giv[33]|new[36]	_	_
4-32	655-658	and	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
4-33	659-674	thromboembolism	abstract[32]|abstract[33]|abstract	new[32]|giv[33]|new	_	_
4-34	675-676	.	_	_	_	_

#Text=There is growing evidence that the HIF pathway is implicated — for better or for worse — in the response of the vascular wall to inadequate oxygenation and/or increased cellular oxygen , a demand secondary to various stresses or injuries .
5-1	677-682	There	_	_	_	_
5-2	683-685	is	_	_	_	_
5-3	686-693	growing	abstract[38]	new[38]	_	_
5-4	694-702	evidence	abstract[38]	new[38]	_	_
5-5	703-707	that	abstract[38]	new[38]	_	_
5-6	708-711	the	abstract[38]|abstract[40]	new[38]|new[40]	coref	21-4[139_40]
5-7	712-715	HIF	abstract[38]|abstract|abstract[40]	new[38]|giv|new[40]	coref	7-1
5-8	716-723	pathway	abstract[38]|abstract[40]	new[38]|new[40]	_	_
5-9	724-726	is	abstract[38]	new[38]	_	_
5-10	727-737	implicated	abstract[38]	new[38]	_	_
5-11	738-739	—	abstract[38]	new[38]	_	_
5-12	740-743	for	abstract[38]	new[38]	_	_
5-13	744-750	better	abstract[38]	new[38]	_	_
5-14	751-753	or	abstract[38]	new[38]	_	_
5-15	754-757	for	abstract[38]	new[38]	_	_
5-16	758-763	worse	abstract[38]	new[38]	_	_
5-17	764-765	—	abstract[38]	new[38]	_	_
5-18	766-768	in	abstract[38]	new[38]	_	_
5-19	769-772	the	abstract[38]|event[41]	new[38]|giv[41]	_	_
5-20	773-781	response	abstract[38]|event[41]	new[38]|giv[41]	_	_
5-21	782-784	of	abstract[38]|event[41]	new[38]|giv[41]	_	_
5-22	785-788	the	abstract[38]|event[41]|object[42]	new[38]|giv[41]|giv[42]	coref	8-14[56_42]
5-23	789-797	vascular	abstract[38]|event[41]|object[42]	new[38]|giv[41]|giv[42]	_	_
5-24	798-802	wall	abstract[38]|event[41]|object[42]	new[38]|giv[41]|giv[42]	_	_
5-25	803-805	to	abstract[38]|event[41]|object[42]	new[38]|giv[41]|giv[42]	_	_
5-26	806-816	inadequate	abstract[38]|event[41]|object[42]|substance[43]	new[38]|giv[41]|giv[42]|new[43]	_	_
5-27	817-828	oxygenation	abstract[38]|event[41]|object[42]|substance[43]	new[38]|giv[41]|giv[42]|new[43]	_	_
5-28	829-835	and/or	abstract[38]|event[41]|object[42]	new[38]|giv[41]|giv[42]	_	_
5-29	836-845	increased	abstract[38]|event[41]|object[42]|substance[44]	new[38]|giv[41]|giv[42]|new[44]	coref	11-8[0_44]
5-30	846-854	cellular	abstract[38]|event[41]|object[42]|substance[44]	new[38]|giv[41]|giv[42]|new[44]	_	_
5-31	855-861	oxygen	abstract[38]|event[41]|object[42]|substance[44]	new[38]|giv[41]|giv[42]|new[44]	_	_
5-32	862-863	,	_	_	_	_
5-33	864-865	a	abstract[45]	new[45]	coref	11-6[73_45]
5-34	866-872	demand	abstract[45]	new[45]	_	_
5-35	873-882	secondary	abstract[45]	new[45]	_	_
5-36	883-885	to	_	_	_	_
5-37	886-893	various	abstract[46]	new[46]	_	_
5-38	894-902	stresses	abstract[46]	new[46]	_	_
5-39	903-905	or	_	_	_	_
5-40	906-914	injuries	event	new	_	_
5-41	915-916	.	_	_	_	_

#Text=6.1.
6-1	917-921	6.1.	abstract	new	_	_

#Text=HIF and Atherosclerosis
7-1	922-925	HIF	abstract|abstract[50]	giv|giv[50]	coref|coref	18-10|20-1[134_50]
7-2	926-929	and	abstract[50]	giv[50]	_	_
7-3	930-945	Atherosclerosis	abstract[50]|abstract	giv[50]|giv	coref	8-1

#Text=Atherosclerosis is a condition in which fatty deposits ( plaques ) develop in the arterial wall , leading to stenosis and ultimately to thrombosis of the vessel .
8-1	946-961	Atherosclerosis	abstract	giv	coref	8-3[53_0]
8-2	962-964	is	_	_	_	_
8-3	965-966	a	abstract[53]	giv[53]	_	_
8-4	967-976	condition	abstract[53]	giv[53]	_	_
8-5	977-979	in	abstract[53]	giv[53]	_	_
8-6	980-985	which	abstract[53]	giv[53]	_	_
8-7	986-991	fatty	abstract[53]|substance[54]	giv[53]|new[54]	_	_
8-8	992-1000	deposits	abstract[53]|substance[54]	giv[53]|new[54]	_	_
8-9	1001-1002	(	abstract[53]	giv[53]	_	_
8-10	1003-1010	plaques	abstract[53]|object	giv[53]|new	coref	9-1[60_0]
8-11	1011-1012	)	abstract[53]	giv[53]	_	_
8-12	1013-1020	develop	abstract[53]|event	giv[53]|new	coref|none	21-8[140_0]|8-12[0_140]
8-13	1021-1023	in	abstract[53]	giv[53]	_	_
8-14	1024-1027	the	abstract[53]|object[56]	giv[53]|giv[56]	coref	10-12[0_56]
8-15	1028-1036	arterial	abstract[53]|object[56]	giv[53]|giv[56]	_	_
8-16	1037-1041	wall	abstract[53]|object[56]	giv[53]|giv[56]	_	_
8-17	1042-1043	,	_	_	_	_
8-18	1044-1051	leading	_	_	_	_
8-19	1052-1054	to	_	_	_	_
8-20	1055-1063	stenosis	abstract	new	_	_
8-21	1064-1067	and	_	_	_	_
8-22	1068-1078	ultimately	event[58]	new[58]	_	_
8-23	1079-1081	to	event[58]	new[58]	_	_
8-24	1082-1092	thrombosis	event[58]	new[58]	_	_
8-25	1093-1095	of	event[58]	new[58]	_	_
8-26	1096-1099	the	event[58]|object[59]	new[58]|new[59]	coref	25-13[0_59]
8-27	1100-1106	vessel	event[58]|object[59]	new[58]|new[59]	_	_
8-28	1107-1108	.	_	_	_	_

#Text=Atherosclerotic plaques are mainly composed of cholesterol , other lipids , calcium , fibrin and inflammatory cells .
9-1	1109-1124	Atherosclerotic	object[60]	giv[60]	coref	10-4[68_60]
9-2	1125-1132	plaques	object[60]	giv[60]	_	_
9-3	1133-1136	are	_	_	_	_
9-4	1137-1143	mainly	_	_	_	_
9-5	1144-1152	composed	_	_	_	_
9-6	1153-1155	of	_	_	_	_
9-7	1156-1167	cholesterol	substance	new	_	_
9-8	1168-1169	,	_	_	_	_
9-9	1170-1175	other	substance[62]	new[62]	_	_
9-10	1176-1182	lipids	substance[62]	new[62]	_	_
9-11	1183-1184	,	_	_	_	_
9-12	1185-1192	calcium	substance	new	_	_
9-13	1193-1194	,	_	_	_	_
9-14	1195-1201	fibrin	substance	new	_	_
9-15	1202-1205	and	_	_	_	_
9-16	1206-1218	inflammatory	place[65]	new[65]	coref	11-11[74_65]
9-17	1219-1224	cells	place[65]	new[65]	_	_
9-18	1225-1226	.	_	_	_	_

#Text=Oxygen diffusion through space-occupying atherosclerotic plaques could be limited due to wall thickening .
10-1	1227-1233	Oxygen	person|abstract[67]	new|new[67]	_	_
10-2	1234-1243	diffusion	abstract[67]	new[67]	_	_
10-3	1244-1251	through	abstract[67]	new[67]	_	_
10-4	1252-1267	space-occupying	abstract[67]|object[68]	new[67]|giv[68]	coref	12-12[85_68]
10-5	1268-1283	atherosclerotic	abstract[67]|object[68]	new[67]|giv[68]	_	_
10-6	1284-1291	plaques	abstract[67]|object[68]	new[67]|giv[68]	_	_
10-7	1292-1297	could	_	_	_	_
10-8	1298-1300	be	_	_	_	_
10-9	1301-1308	limited	_	_	_	_
10-10	1309-1312	due	_	_	_	_
10-11	1313-1315	to	_	_	_	_
10-12	1316-1320	wall	object|abstract[70]	giv|new[70]	coref	25-12[172_0]
10-13	1321-1331	thickening	abstract[70]	new[70]	_	_
10-14	1332-1333	.	_	_	_	_

#Text=Hypoxia could also originate from the high oxygen demand of metabolically active inflammatory cells , such as macrophage foam cells that play a pivotal role in this disease .
11-1	1334-1341	Hypoxia	abstract	giv	coref	13-8
11-2	1342-1347	could	_	_	_	_
11-3	1348-1352	also	_	_	_	_
11-4	1353-1362	originate	_	_	_	_
11-5	1363-1367	from	_	_	_	_
11-6	1368-1371	the	abstract[73]	giv[73]	_	_
11-7	1372-1376	high	abstract[73]	giv[73]	_	_
11-8	1377-1383	oxygen	substance|abstract[73]	giv|giv[73]	coref	13-20[93_0]
11-9	1384-1390	demand	abstract[73]	giv[73]	_	_
11-10	1391-1393	of	abstract[73]	giv[73]	_	_
11-11	1394-1407	metabolically	abstract[73]|place[74]	giv[73]|giv[74]	coref	11-18[77_74]
11-12	1408-1414	active	abstract[73]|place[74]	giv[73]|giv[74]	_	_
11-13	1415-1427	inflammatory	abstract[73]|place[74]	giv[73]|giv[74]	_	_
11-14	1428-1433	cells	abstract[73]|place[74]	giv[73]|giv[74]	_	_
11-15	1434-1435	,	abstract[73]|place[74]	giv[73]|giv[74]	_	_
11-16	1436-1440	such	abstract[73]|place[74]	giv[73]|giv[74]	_	_
11-17	1441-1443	as	abstract[73]|place[74]	giv[73]|giv[74]	_	_
11-18	1444-1454	macrophage	abstract[73]|place[74]|place|place[77]	giv[73]|giv[74]|new|giv[77]	_	_
11-19	1455-1459	foam	abstract[73]|place[74]|substance|place[77]	giv[73]|giv[74]|new|giv[77]	_	_
11-20	1460-1465	cells	abstract[73]|place[74]|place[77]	giv[73]|giv[74]|giv[77]	_	_
11-21	1466-1470	that	abstract[73]|place[74]|place[77]	giv[73]|giv[74]|giv[77]	_	_
11-22	1471-1475	play	abstract[73]|place[74]|place[77]	giv[73]|giv[74]|giv[77]	_	_
11-23	1476-1477	a	abstract[73]|place[74]|place[77]|abstract[78]	giv[73]|giv[74]|giv[77]|new[78]	coref	21-1[137_78]
11-24	1478-1485	pivotal	abstract[73]|place[74]|place[77]|abstract[78]	giv[73]|giv[74]|giv[77]|new[78]	_	_
11-25	1486-1490	role	abstract[73]|place[74]|place[77]|abstract[78]	giv[73]|giv[74]|giv[77]|new[78]	_	_
11-26	1491-1493	in	abstract[73]|place[74]|place[77]|abstract[78]	giv[73]|giv[74]|giv[77]|new[78]	_	_
11-27	1494-1498	this	abstract[73]|place[74]|place[77]|abstract[78]|abstract[79]	giv[73]|giv[74]|giv[77]|new[78]|giv[79]	_	_
11-28	1499-1506	disease	abstract[73]|place[74]|place[77]|abstract[78]|abstract[79]	giv[73]|giv[74]|giv[77]|new[78]|giv[79]	_	_
11-29	1507-1508	.	_	_	_	_

#Text=Detection of HIF-1α and activation of its target genes occurs in atherosclerotic plaques .
12-1	1509-1518	Detection	abstract[80]	new[80]	_	_
12-2	1519-1521	of	abstract[80]	new[80]	_	_
12-3	1522-1528	HIF-1α	abstract[80]|abstract	new[80]|new	ana	12-7
12-4	1529-1532	and	_	_	_	_
12-5	1533-1543	activation	event[82]	new[82]	_	_
12-6	1544-1546	of	event[82]	new[82]	_	_
12-7	1547-1550	its	event[82]|abstract|abstract[84]	new[82]|giv|new[84]	coref|coref	15-2|16-1[110_84]
12-8	1551-1557	target	event[82]|abstract[84]	new[82]|new[84]	_	_
12-9	1558-1563	genes	event[82]|abstract[84]	new[82]|new[84]	_	_
12-10	1564-1570	occurs	_	_	_	_
12-11	1571-1573	in	_	_	_	_
12-12	1574-1589	atherosclerotic	object[85]	giv[85]	coref	14-4[97_85]
12-13	1590-1597	plaques	object[85]	giv[85]	_	_
12-14	1598-1599	.	_	_	_	_

#Text=During atherogenesis ( plaque build-up ) , hypoxia increases angiogenesis , releases pro-inflammatory mediators , activates MMPs , forms reactive oxygen species , and oxidizes low-density lipoprotein .
13-1	1600-1606	During	_	_	_	_
13-2	1607-1620	atherogenesis	abstract	new	_	_
13-3	1621-1622	(	_	_	_	_
13-4	1623-1629	plaque	object|event[88]	new|new[88]	coref	14-9
13-5	1630-1638	build-up	event[88]	new[88]	_	_
13-6	1639-1640	)	_	_	_	_
13-7	1641-1642	,	_	_	_	_
13-8	1643-1650	hypoxia	abstract	giv	coref	18-4
13-9	1651-1660	increases	_	_	_	_
13-10	1661-1673	angiogenesis	abstract	new	_	_
13-11	1674-1675	,	_	_	_	_
13-12	1676-1684	releases	_	_	_	_
13-13	1685-1701	pro-inflammatory	person[91]	new[91]	_	_
13-14	1702-1711	mediators	person[91]	new[91]	_	_
13-15	1712-1713	,	_	_	_	_
13-16	1714-1723	activates	_	_	_	_
13-17	1724-1728	MMPs	abstract	new	_	_
13-18	1729-1730	,	_	_	_	_
13-19	1731-1736	forms	_	_	_	_
13-20	1737-1745	reactive	substance[93]|abstract[94]	giv[93]|new[94]	coref	24-16[0_93]
13-21	1746-1752	oxygen	substance[93]|abstract[94]	giv[93]|new[94]	_	_
13-22	1753-1760	species	abstract[94]	new[94]	_	_
13-23	1761-1762	,	_	_	_	_
13-24	1763-1766	and	_	_	_	_
13-25	1767-1775	oxidizes	_	_	_	_
13-26	1776-1787	low-density	substance[95]	new[95]	_	_
13-27	1788-1799	lipoprotein	substance[95]	new[95]	_	_
13-28	1800-1801	.	_	_	_	_

#Text=Necrotic cores within atherosclerotic plaques can lead to plaque instability and thromboembolic complications .
14-1	1802-1810	Necrotic	object[96]	new[96]	coref	15-18[108_96]
14-2	1811-1816	cores	object[96]	new[96]	_	_
14-3	1817-1823	within	object[96]	new[96]	_	_
14-4	1824-1839	atherosclerotic	object[96]|object[97]	new[96]|giv[97]	coref	18-16[0_97]
14-5	1840-1847	plaques	object[96]|object[97]	new[96]|giv[97]	_	_
14-6	1848-1851	can	_	_	_	_
14-7	1852-1856	lead	_	_	_	_
14-8	1857-1859	to	_	_	_	_
14-9	1860-1866	plaque	object|abstract[99]	giv|new[99]	coref|coref	16-17|16-17[114_99]
14-10	1867-1878	instability	abstract[99]	new[99]	_	_
14-11	1879-1882	and	_	_	_	_
14-12	1883-1897	thromboembolic	event[100]	new[100]	_	_
14-13	1898-1911	complications	event[100]	new[100]	_	_
14-14	1912-1913	.	_	_	_	_

#Text=The HIF-1α protein is found in tissue surrounding atherosclerotic arteries , inflammatory macrophages and arterial SMCs around these necrotic cores .
15-1	1914-1917	The	substance[102]	new[102]	_	_
15-2	1918-1924	HIF-1α	abstract|substance[102]	giv|new[102]	coref	26-11
15-3	1925-1932	protein	substance[102]	new[102]	_	_
15-4	1933-1935	is	_	_	_	_
15-5	1936-1941	found	_	_	_	_
15-6	1942-1944	in	_	_	_	_
15-7	1945-1951	tissue	substance[103]	giv[103]	_	_
15-8	1952-1963	surrounding	substance[103]	giv[103]	_	_
15-9	1964-1979	atherosclerotic	substance[103]|object[104]|object[105]	giv[103]|giv[104]|giv[105]	coref	15-9[105_104]
15-10	1980-1988	arteries	substance[103]|object[104]|object[105]	giv[103]|giv[104]|giv[105]	_	_
15-11	1989-1990	,	substance[103]|object[105]	giv[103]|giv[105]	_	_
15-12	1991-2003	inflammatory	substance[103]|object[105]|animal[106]	giv[103]|giv[105]|new[106]	coref	17-9[0_106]
15-13	2004-2015	macrophages	substance[103]|object[105]|animal[106]	giv[103]|giv[105]|new[106]	_	_
15-14	2016-2019	and	substance[103]|object[105]	giv[103]|giv[105]	_	_
15-15	2020-2028	arterial	substance[103]|object[105]|abstract[107]	giv[103]|giv[105]|new[107]	_	_
15-16	2029-2033	SMCs	substance[103]|object[105]|abstract[107]	giv[103]|giv[105]|new[107]	_	_
15-17	2034-2040	around	substance[103]|object[105]|abstract[107]	giv[103]|giv[105]|new[107]	_	_
15-18	2041-2046	these	substance[103]|object[105]|abstract[107]|object[108]	giv[103]|giv[105]|new[107]|giv[108]	_	_
15-19	2047-2055	necrotic	substance[103]|object[105]|abstract[107]|object[108]	giv[103]|giv[105]|new[107]|giv[108]	_	_
15-20	2056-2061	cores	substance[103]|object[105]|abstract[107]|object[108]	giv[103]|giv[105]|new[107]|giv[108]	_	_
15-21	2062-2063	.	_	_	_	_

#Text=Proangiogenic HIF-target genes , such as VEGF-A , are responsible for intra-plaque neoangiogenesis , contributing to plaque instability .
16-1	2064-2077	Proangiogenic	abstract[110]	giv[110]	_	_
16-2	2078-2088	HIF-target	abstract|abstract[110]	new|giv[110]	_	_
16-3	2089-2094	genes	abstract[110]	giv[110]	_	_
16-4	2095-2096	,	abstract[110]	giv[110]	_	_
16-5	2097-2101	such	abstract[110]	giv[110]	_	_
16-6	2102-2104	as	abstract[110]	giv[110]	_	_
16-7	2105-2111	VEGF-A	abstract[110]|abstract	giv[110]|new	_	_
16-8	2112-2113	,	_	_	_	_
16-9	2114-2117	are	_	_	_	_
16-10	2118-2129	responsible	_	_	_	_
16-11	2130-2133	for	_	_	_	_
16-12	2134-2146	intra-plaque	abstract[112]	new[112]	_	_
16-13	2147-2162	neoangiogenesis	abstract[112]	new[112]	_	_
16-14	2163-2164	,	_	_	_	_
16-15	2165-2177	contributing	_	_	_	_
16-16	2178-2180	to	_	_	_	_
16-17	2181-2187	plaque	object|abstract[114]	giv|giv[114]	coref	18-18
16-18	2188-2199	instability	abstract[114]	giv[114]	_	_
16-19	2200-2201	.	_	_	_	_

#Text=HIF-1 activity also alters the lipid metabolism of macrophages and vascular SMC .
17-1	2202-2207	HIF-1	substance|abstract[116]	new|new[116]	_	_
17-2	2208-2216	activity	abstract[116]	new[116]	_	_
17-3	2217-2221	also	_	_	_	_
17-4	2222-2228	alters	_	_	_	_
17-5	2229-2232	the	abstract[118]	new[118]	coref	34-24[0_118]
17-6	2233-2238	lipid	substance|abstract[118]	new|new[118]	_	_
17-7	2239-2249	metabolism	abstract[118]	new[118]	_	_
17-8	2250-2252	of	abstract[118]	new[118]	_	_
17-9	2253-2264	macrophages	abstract[118]|animal|animal[120]	new[118]|giv|giv[120]	coref|coref	17-9[120_0]|18-18[128_120]
17-10	2265-2268	and	abstract[118]|animal[120]	new[118]|giv[120]	_	_
17-11	2269-2277	vascular	abstract[118]|animal[120]|abstract[121]	new[118]|giv[120]|new[121]	_	_
17-12	2278-2281	SMC	abstract[118]|animal[120]|abstract[121]	new[118]|giv[120]|new[121]	_	_
17-13	2282-2283	.	_	_	_	_

#Text=Finally , besides hypoxia , several non-hypoxic stimuli of HIF have also been found in plaques and plaque macrophages , such as inflammation , ROS , vasoactive and thrombotic factors .
18-1	2284-2291	Finally	_	_	_	_
18-2	2292-2293	,	_	_	_	_
18-3	2294-2301	besides	_	_	_	_
18-4	2302-2309	hypoxia	abstract	giv	coref	25-9[170_0]
18-5	2310-2311	,	_	_	_	_
18-6	2312-2319	several	abstract[123]	new[123]	_	_
18-7	2320-2331	non-hypoxic	abstract[123]	new[123]	_	_
18-8	2332-2339	stimuli	abstract[123]	new[123]	_	_
18-9	2340-2342	of	abstract[123]	new[123]	_	_
18-10	2343-2346	HIF	abstract[123]|abstract	new[123]|giv	coref	20-1
18-11	2347-2351	have	_	_	_	_
18-12	2352-2356	also	_	_	_	_
18-13	2357-2361	been	_	_	_	_
18-14	2362-2367	found	_	_	_	_
18-15	2368-2370	in	_	_	_	_
18-16	2371-2378	plaques	object|object[126]	giv|giv[126]	coref	18-16[126_0]
18-17	2379-2382	and	object[126]	giv[126]	_	_
18-18	2383-2389	plaque	object[126]|object|animal[128]	giv[126]|giv|giv[128]	_	_
18-19	2390-2401	macrophages	object[126]|animal[128]	giv[126]|giv[128]	_	_
18-20	2402-2403	,	_	_	_	_
18-21	2404-2408	such	_	_	_	_
18-22	2409-2411	as	_	_	_	_
18-23	2412-2424	inflammation	abstract	new	_	_
18-24	2425-2426	,	_	_	_	_
18-25	2427-2430	ROS	substance	new	coref	34-16
18-26	2431-2432	,	_	_	_	_
18-27	2433-2443	vasoactive	_	_	_	_
18-28	2444-2447	and	_	_	_	_
18-29	2448-2458	thrombotic	abstract[131]	new[131]	_	_
18-30	2459-2466	factors	abstract[131]	new[131]	_	_
18-31	2467-2468	.	_	_	_	_

#Text=6.2.
19-1	2469-2473	6.2.	abstract	new	_	_

#Text=HIF and NH in Vascular Grafts
20-1	2474-2477	HIF	abstract|abstract[134]	giv|giv[134]	coref	21-5
20-2	2478-2481	and	abstract[134]	giv[134]	_	_
20-3	2482-2484	NH	abstract[134]|abstract[135]	giv[134]|new[135]	coref	21-11[0_135]
20-4	2485-2487	in	abstract[134]|abstract[135]	giv[134]|new[135]	_	_
20-5	2488-2496	Vascular	abstract[134]|abstract[135]|object[136]	giv[134]|new[135]|new[136]	coref	23-6[150_136]
20-6	2497-2503	Grafts	abstract[134]|abstract[135]|object[136]	giv[134]|new[135]|new[136]	_	_

#Text=The role of the HIF pathway in the development of NH has also been studied .
21-1	2504-2507	The	abstract[137]	giv[137]	_	_
21-2	2508-2512	role	abstract[137]	giv[137]	_	_
21-3	2513-2515	of	abstract[137]	giv[137]	_	_
21-4	2516-2519	the	abstract[137]|abstract[139]	giv[137]|giv[139]	coref	27-6[191_139]
21-5	2520-2523	HIF	abstract[137]|abstract|abstract[139]	giv[137]|giv|giv[139]	coref	27-7
21-6	2524-2531	pathway	abstract[137]|abstract[139]	giv[137]|giv[139]	_	_
21-7	2532-2534	in	abstract[137]	giv[137]	_	_
21-8	2535-2538	the	abstract[137]|event[140]	giv[137]|new[140]	_	_
21-9	2539-2550	development	abstract[137]|event[140]	giv[137]|new[140]	_	_
21-10	2551-2553	of	abstract[137]|event[140]	giv[137]|new[140]	_	_
21-11	2554-2556	NH	abstract[137]|event[140]|abstract	giv[137]|new[140]|giv	coref	23-11
21-12	2557-2560	has	_	_	_	_
21-13	2561-2565	also	_	_	_	_
21-14	2566-2570	been	_	_	_	_
21-15	2571-2578	studied	_	_	_	_
21-16	2579-2580	.	_	_	_	_

#Text=When atherosclerotic lesions occupy a long segment of the artery , surgeons frequently use a graft to bypass the lesion and provide blood to distal tissues .
22-1	2581-2585	When	_	_	_	_
22-2	2586-2601	atherosclerotic	object[142]	new[142]	_	_
22-3	2602-2609	lesions	object[142]	new[142]	_	_
22-4	2610-2616	occupy	_	_	_	_
22-5	2617-2618	a	place[143]	new[143]	_	_
22-6	2619-2623	long	place[143]	new[143]	_	_
22-7	2624-2631	segment	place[143]	new[143]	_	_
22-8	2632-2634	of	place[143]	new[143]	_	_
22-9	2635-2638	the	place[143]|object[144]	new[143]|new[144]	_	_
22-10	2639-2645	artery	place[143]|object[144]	new[143]|new[144]	_	_
22-11	2646-2647	,	_	_	_	_
22-12	2648-2656	surgeons	person	new	_	_
22-13	2657-2667	frequently	_	_	_	_
22-14	2668-2671	use	_	_	_	_
22-15	2672-2673	a	object[146]	new[146]	coref	29-4[204_146]
22-16	2674-2679	graft	object[146]	new[146]	_	_
22-17	2680-2682	to	_	_	_	_
22-18	2683-2689	bypass	_	_	_	_
22-19	2690-2693	the	object[147]	new[147]	_	_
22-20	2694-2700	lesion	object[147]	new[147]	_	_
22-21	2701-2704	and	_	_	_	_
22-22	2705-2712	provide	_	_	_	_
22-23	2713-2718	blood	substance	giv	_	_
22-24	2719-2721	to	_	_	_	_
22-25	2722-2728	distal	object[149]	new[149]	_	_
22-26	2729-2736	tissues	object[149]	new[149]	_	_
22-27	2737-2738	.	_	_	_	_

#Text=Either venous or prosthetic , these grafts are prone to NH .
23-1	2739-2745	Either	_	_	_	_
23-2	2746-2752	venous	_	_	_	_
23-3	2753-2755	or	_	_	_	_
23-4	2756-2766	prosthetic	_	_	_	_
23-5	2767-2768	,	_	_	_	_
23-6	2769-2774	these	object[150]	giv[150]	coref	24-2[153_150]
23-7	2775-2781	grafts	object[150]	giv[150]	_	_
23-8	2782-2785	are	_	_	_	_
23-9	2786-2791	prone	_	_	_	_
23-10	2792-2794	to	_	_	_	_
23-11	2795-2797	NH	abstract	giv	coref	24-22[160_0]
23-12	2798-2799	.	_	_	_	_

#Text=Although vein grafts and prosthetic grafts are not identical , because of different hemodynamics and oxygen tension , the characteristics of NH in vein grafts are similar to those of NH that form in AVFs .
24-1	2800-2808	Although	_	_	_	_
24-2	2809-2813	vein	object|object[153]|object[154]	new|giv[153]|giv[154]	coref|coref|coref	24-2[154_153]|8-12[0_154]|24-24
24-3	2814-2820	grafts	object[153]|object[154]	giv[153]|giv[154]	_	_
24-4	2821-2824	and	object[154]	giv[154]	_	_
24-5	2825-2835	prosthetic	object[154]|object[155]	giv[154]|giv[155]	coref	24-24[162_0]
24-6	2836-2842	grafts	object[154]|object[155]	giv[154]|giv[155]	_	_
24-7	2843-2846	are	_	_	_	_
24-8	2847-2850	not	_	_	_	_
24-9	2851-2860	identical	_	_	_	_
24-10	2861-2862	,	_	_	_	_
24-11	2863-2870	because	_	_	_	_
24-12	2871-2873	of	_	_	_	_
24-13	2874-2883	different	abstract[156]	new[156]	_	_
24-14	2884-2896	hemodynamics	abstract[156]	new[156]	_	_
24-15	2897-2900	and	_	_	_	_
24-16	2901-2907	oxygen	substance|abstract[158]	giv|new[158]	coref	34-10
24-17	2908-2915	tension	abstract[158]	new[158]	_	_
24-18	2916-2917	,	_	_	_	_
24-19	2918-2921	the	abstract[159]	new[159]	_	_
24-20	2922-2937	characteristics	abstract[159]	new[159]	_	_
24-21	2938-2940	of	abstract[159]	new[159]	_	_
24-22	2941-2943	NH	abstract[159]|abstract[160]	new[159]|giv[160]	ana	24-29[163_160]
24-23	2944-2946	in	abstract[159]|abstract[160]	new[159]|giv[160]	_	_
24-24	2947-2951	vein	abstract[159]|abstract[160]|object|object[162]	new[159]|giv[160]|giv|giv[162]	coref|coref	25-7[0_162]|29-5
24-25	2952-2958	grafts	abstract[159]|abstract[160]|object[162]	new[159]|giv[160]|giv[162]	_	_
24-26	2959-2962	are	_	_	_	_
24-27	2963-2970	similar	_	_	_	_
24-28	2971-2973	to	_	_	_	_
24-29	2974-2979	those	abstract[163]	giv[163]	coref	24-31[164_163]
24-30	2980-2982	of	abstract[163]	giv[163]	_	_
24-31	2983-2985	NH	abstract[163]|abstract[164]	giv[163]|giv[164]	coref	26-30[0_164]
24-32	2986-2990	that	abstract[163]|abstract[164]	giv[163]|giv[164]	_	_
24-33	2991-2995	form	abstract[163]|abstract[164]	giv[163]|giv[164]	_	_
24-34	2996-2998	in	abstract[163]|abstract[164]	giv[163]|giv[164]	_	_
24-35	2999-3003	AVFs	abstract[163]|abstract[164]|abstract	giv[163]|giv[164]|new	_	_
24-36	3004-3005	.	_	_	_	_

#Text=In studies with animal models , grafts showed increased hypoxia within the vessel wall in regions of neointimal hyperplasia .
25-1	3006-3008	In	_	_	_	_
25-2	3009-3016	studies	abstract[166]	new[166]	coref	33-1[237_166]
25-3	3017-3021	with	abstract[166]	new[166]	_	_
25-4	3022-3028	animal	abstract[166]|person|abstract[168]	new[166]|new|new[168]	_	_
25-5	3029-3035	models	abstract[166]|abstract[168]	new[166]|new[168]	_	_
25-6	3036-3037	,	_	_	_	_
25-7	3038-3044	grafts	object	giv	coref	26-20
25-8	3045-3051	showed	_	_	_	_
25-9	3052-3061	increased	abstract[170]	giv[170]	coref	26-26[0_170]
25-10	3062-3069	hypoxia	abstract[170]	giv[170]	_	_
25-11	3070-3076	within	abstract[170]	giv[170]	_	_
25-12	3077-3080	the	abstract[170]|object[172]	giv[170]|giv[172]	coref	33-26[245_172]
25-13	3081-3087	vessel	abstract[170]|object|object[172]	giv[170]|giv|giv[172]	_	_
25-14	3088-3092	wall	abstract[170]|object[172]	giv[170]|giv[172]	_	_
25-15	3093-3095	in	_	_	_	_
25-16	3096-3103	regions	place[173]	new[173]	_	_
25-17	3104-3106	of	place[173]	new[173]	_	_
25-18	3107-3117	neointimal	place[173]|abstract[174]	new[173]|new[174]	coref	26-17[181_174]
25-19	3118-3129	hyperplasia	place[173]|abstract[174]	new[173]|new[174]	_	_
25-20	3130-3131	.	_	_	_	_

#Text=A study using a porcine model showed an association of HIF-1α expression with the degree of neointimal hyperplasia in grafts , and suggested that reducing hypoxia might inhibit venous NH formation , possibly by reducing the phenotypic switch of fibroblasts to myofibroblasts .
26-1	3132-3133	A	abstract[175]	new[175]	_	_
26-2	3134-3139	study	abstract[175]	new[175]	_	_
26-3	3140-3145	using	abstract[175]	new[175]	_	_
26-4	3146-3147	a	abstract[175]|abstract[176]	new[175]|new[176]	_	_
26-5	3148-3155	porcine	abstract[175]|abstract[176]	new[175]|new[176]	_	_
26-6	3156-3161	model	abstract[175]|abstract[176]	new[175]|new[176]	_	_
26-7	3162-3168	showed	_	_	_	_
26-8	3169-3171	an	abstract[177]	new[177]	_	_
26-9	3172-3183	association	abstract[177]	new[177]	_	_
26-10	3184-3186	of	abstract[177]	new[177]	_	_
26-11	3187-3193	HIF-1α	abstract[177]|abstract|abstract[179]	new[177]|giv|new[179]	coref|coref	31-15[221_0]|31-18[223_179]
26-12	3194-3204	expression	abstract[177]|abstract[179]	new[177]|new[179]	_	_
26-13	3205-3209	with	abstract[177]	new[177]	_	_
26-14	3210-3213	the	abstract[177]|abstract[180]	new[177]|new[180]	_	_
26-15	3214-3220	degree	abstract[177]|abstract[180]	new[177]|new[180]	_	_
26-16	3221-3223	of	abstract[177]|abstract[180]	new[177]|new[180]	_	_
26-17	3224-3234	neointimal	abstract[177]|abstract[180]|abstract[181]	new[177]|new[180]|giv[181]	_	_
26-18	3235-3246	hyperplasia	abstract[177]|abstract[180]|abstract[181]	new[177]|new[180]|giv[181]	_	_
26-19	3247-3249	in	abstract[177]|abstract[180]	new[177]|new[180]	_	_
26-20	3250-3256	grafts	abstract[177]|abstract[180]|object	new[177]|new[180]|giv	_	_
26-21	3257-3258	,	_	_	_	_
26-22	3259-3262	and	_	_	_	_
26-23	3263-3272	suggested	_	_	_	_
26-24	3273-3277	that	_	_	_	_
26-25	3278-3286	reducing	_	_	_	_
26-26	3287-3294	hypoxia	abstract	giv	coref	33-29
26-27	3295-3300	might	_	_	_	_
26-28	3301-3308	inhibit	_	_	_	_
26-29	3309-3315	venous	event[185]	new[185]	coref	27-13[193_185]
26-30	3316-3318	NH	abstract|event[185]	giv|new[185]	coref	27-13
26-31	3319-3328	formation	event[185]	new[185]	_	_
26-32	3329-3330	,	_	_	_	_
26-33	3331-3339	possibly	_	_	_	_
26-34	3340-3342	by	_	_	_	_
26-35	3343-3351	reducing	_	_	_	_
26-36	3352-3355	the	event[186]	new[186]	_	_
26-37	3356-3366	phenotypic	event[186]	new[186]	_	_
26-38	3367-3373	switch	event[186]	new[186]	_	_
26-39	3374-3376	of	event[186]	new[186]	_	_
26-40	3377-3388	fibroblasts	event[186]|object	new[186]|new	_	_
26-41	3389-3391	to	event[186]	new[186]	_	_
26-42	3392-3406	myofibroblasts	event[186]|person	new[186]|new	ana	29-1
26-43	3407-3408	.	_	_	_	_

#Text=Paradoxically , increased activation of the HIF pathway may also protect against NH formation .
27-1	3409-3422	Paradoxically	_	_	_	_
27-2	3423-3424	,	_	_	_	_
27-3	3425-3434	increased	event[189]	new[189]	_	_
27-4	3435-3445	activation	event[189]	new[189]	_	_
27-5	3446-3448	of	event[189]	new[189]	_	_
27-6	3449-3452	the	event[189]|abstract[191]	new[189]|giv[191]	coref	32-33[236_191]
27-7	3453-3456	HIF	event[189]|abstract|abstract[191]	new[189]|giv|giv[191]	coref	32-34
27-8	3457-3464	pathway	event[189]|abstract[191]	new[189]|giv[191]	_	_
27-9	3465-3468	may	_	_	_	_
27-10	3469-3473	also	_	_	_	_
27-11	3474-3481	protect	_	_	_	_
27-12	3482-3489	against	_	_	_	_
27-13	3490-3492	NH	abstract|event[193]	giv|giv[193]	coref|coref	28-23[200_193]|28-26
27-14	3493-3502	formation	event[193]	giv[193]	_	_
27-15	3503-3504	.	_	_	_	_

#Text=Nakao et al. studied the role of carbon monoxide , a physiologically important vasodilator that acts via cyclic guanosine monophosphate , in the formation of NH .
28-1	3505-3510	Nakao	person	new	_	_
28-2	3511-3513	et	_	_	_	_
28-3	3514-3517	al.	_	_	_	_
28-4	3518-3525	studied	_	_	_	_
28-5	3526-3529	the	abstract[195]	new[195]	_	_
28-6	3530-3534	role	abstract[195]	new[195]	_	_
28-7	3535-3537	of	abstract[195]	new[195]	_	_
28-8	3538-3544	carbon	abstract[195]|substance[196]	new[195]|new[196]	coref	30-11[213_196]
28-9	3545-3553	monoxide	abstract[195]|substance[196]	new[195]|new[196]	_	_
28-10	3554-3555	,	_	_	_	_
28-11	3556-3557	a	object[197]	new[197]	_	_
28-12	3558-3573	physiologically	object[197]	new[197]	_	_
28-13	3574-3583	important	object[197]	new[197]	_	_
28-14	3584-3595	vasodilator	object[197]	new[197]	_	_
28-15	3596-3600	that	object[197]	new[197]	_	_
28-16	3601-3605	acts	object[197]	new[197]	_	_
28-17	3606-3609	via	object[197]	new[197]	_	_
28-18	3610-3616	cyclic	object[197]|substance[199]	new[197]|new[199]	_	_
28-19	3617-3626	guanosine	object[197]|abstract|substance[199]	new[197]|new|new[199]	_	_
28-20	3627-3640	monophosphate	object[197]|substance[199]	new[197]|new[199]	_	_
28-21	3641-3642	,	_	_	_	_
28-22	3643-3645	in	_	_	_	_
28-23	3646-3649	the	event[200]	giv[200]	coref	31-8[220_200]
28-24	3650-3659	formation	event[200]	giv[200]	_	_
28-25	3660-3662	of	event[200]	giv[200]	_	_
28-26	3663-3665	NH	event[200]|abstract	giv[200]|giv	coref	29-13[206_0]
28-27	3666-3667	.	_	_	_	_

#Text=They showed that a vein graft placed immediately after harvest led to less NH than if the graft was rinsed with lactated Ringer for 2 h prior to surgical placement .
29-1	3668-3672	They	person	giv	_	_
29-2	3673-3679	showed	_	_	_	_
29-3	3680-3684	that	_	_	_	_
29-4	3685-3686	a	object[204]	giv[204]	coref	29-17[207_204]
29-5	3687-3691	vein	object|object[204]	giv|giv[204]	coref	33-14
29-6	3692-3697	graft	object[204]	giv[204]	_	_
29-7	3698-3704	placed	object[204]	giv[204]	_	_
29-8	3705-3716	immediately	object[204]	giv[204]	_	_
29-9	3717-3722	after	object[204]	giv[204]	_	_
29-10	3723-3730	harvest	object[204]|event	giv[204]|new	_	_
29-11	3731-3734	led	_	_	_	_
29-12	3735-3737	to	_	_	_	_
29-13	3738-3742	less	abstract[206]	giv[206]	coref	30-17[0_206]
29-14	3743-3745	NH	abstract[206]	giv[206]	_	_
29-15	3746-3750	than	_	_	_	_
29-16	3751-3753	if	_	_	_	_
29-17	3754-3757	the	object[207]	giv[207]	coref	33-14[240_207]
29-18	3758-3763	graft	object[207]	giv[207]	_	_
29-19	3764-3767	was	_	_	_	_
29-20	3768-3774	rinsed	_	_	_	_
29-21	3775-3779	with	_	_	_	_
29-22	3780-3788	lactated	person[208]	new[208]	coref	30-6[0_208]
29-23	3789-3795	Ringer	person[208]	new[208]	_	_
29-24	3796-3799	for	_	_	_	_
29-25	3800-3801	2	time[209]	new[209]	_	_
29-26	3802-3803	h	time[209]	new[209]	_	_
29-27	3804-3809	prior	_	_	_	_
29-28	3810-3812	to	_	_	_	_
29-29	3813-3821	surgical	event[210]	new[210]	_	_
29-30	3822-3831	placement	event[210]	new[210]	_	_
29-31	3832-3833	.	_	_	_	_

#Text=However , if the lactated Ringer solution was saturated with carbon monoxide , it significantly inhibited NH compared to the untreated control .
30-1	3834-3841	However	_	_	_	_
30-2	3842-3843	,	_	_	_	_
30-3	3844-3846	if	_	_	_	_
30-4	3847-3850	the	substance[212]	new[212]	_	_
30-5	3851-3859	lactated	substance[212]	new[212]	_	_
30-6	3860-3866	Ringer	person|substance[212]	giv|new[212]	_	_
30-7	3867-3875	solution	substance[212]	new[212]	_	_
30-8	3876-3879	was	_	_	_	_
30-9	3880-3889	saturated	_	_	_	_
30-10	3890-3894	with	_	_	_	_
30-11	3895-3901	carbon	substance[213]	giv[213]	ana	30-14[0_213]
30-12	3902-3910	monoxide	substance[213]	giv[213]	_	_
30-13	3911-3912	,	_	_	_	_
30-14	3913-3915	it	substance	giv	coref	31-4[218_0]
30-15	3916-3929	significantly	_	_	_	_
30-16	3930-3939	inhibited	_	_	_	_
30-17	3940-3942	NH	abstract	giv	coref	31-8
30-18	3943-3951	compared	_	_	_	_
30-19	3952-3954	to	_	_	_	_
30-20	3955-3958	the	abstract[216]	new[216]	_	_
30-21	3959-3968	untreated	abstract[216]	new[216]	_	_
30-22	3969-3976	control	abstract[216]	new[216]	_	_
30-23	3977-3978	.	_	_	_	_

#Text=The effects of carbon monoxide in inhibiting NH formation seemed to be associated with increased HIF-1α and VEGF expression a few hours after grafting .
31-1	3979-3982	The	abstract[217]	new[217]	coref	32-25[233_217]
31-2	3983-3990	effects	abstract[217]	new[217]	_	_
31-3	3991-3993	of	abstract[217]	new[217]	_	_
31-4	3994-4000	carbon	abstract[217]|substance[218]	new[217]|giv[218]	coref	34-1[250_218]
31-5	4001-4009	monoxide	abstract[217]|substance[218]	new[217]|giv[218]	_	_
31-6	4010-4012	in	abstract[217]	new[217]	_	_
31-7	4013-4023	inhibiting	abstract[217]	new[217]	_	_
31-8	4024-4026	NH	abstract[217]|abstract|event[220]	new[217]|giv|giv[220]	coref	33-14[241_0]
31-9	4027-4036	formation	abstract[217]|event[220]	new[217]|giv[220]	_	_
31-10	4037-4043	seemed	_	_	_	_
31-11	4044-4046	to	_	_	_	_
31-12	4047-4049	be	_	_	_	_
31-13	4050-4060	associated	_	_	_	_
31-14	4061-4065	with	_	_	_	_
31-15	4066-4075	increased	abstract[221]	giv[221]	coref	32-18[0_221]
31-16	4076-4082	HIF-1α	abstract[221]	giv[221]	_	_
31-17	4083-4086	and	_	_	_	_
31-18	4087-4091	VEGF	person|abstract[223]	new|giv[223]	_	_
31-19	4092-4102	expression	abstract[223]	giv[223]	_	_
31-20	4103-4104	a	abstract[223]|time[224]	giv[223]|new[224]	_	_
31-21	4105-4108	few	abstract[223]|time[224]	giv[223]|new[224]	_	_
31-22	4109-4114	hours	abstract[223]|time[224]	giv[223]|new[224]	_	_
31-23	4115-4120	after	abstract[223]|time[224]	giv[223]|new[224]	_	_
31-24	4121-4129	grafting	abstract[223]|time[224]	giv[223]|new[224]	_	_
31-25	4130-4131	.	_	_	_	_

#Text=This effect , including the induction of VEGF , was reversed by treatment with YC-1 , a HIF-1α inhibitor , supporting the conclusion that these effects were mediated through the activation of the HIF pathway .
32-1	4132-4136	This	abstract[225]	new[225]	_	_
32-2	4137-4143	effect	abstract[225]	new[225]	_	_
32-3	4144-4145	,	abstract[225]	new[225]	_	_
32-4	4146-4155	including	abstract[225]	new[225]	_	_
32-5	4156-4159	the	abstract[225]|event[226]	new[225]|new[226]	_	_
32-6	4160-4169	induction	abstract[225]|event[226]	new[225]|new[226]	_	_
32-7	4170-4172	of	abstract[225]|event[226]	new[225]|new[226]	_	_
32-8	4173-4177	VEGF	abstract[225]|event[226]|abstract	new[225]|new[226]|new	_	_
32-9	4178-4179	,	_	_	_	_
32-10	4180-4183	was	_	_	_	_
32-11	4184-4192	reversed	_	_	_	_
32-12	4193-4195	by	_	_	_	_
32-13	4196-4205	treatment	event[228]	new[228]	_	_
32-14	4206-4210	with	event[228]	new[228]	_	_
32-15	4211-4215	YC-1	event[228]|abstract	new[228]|new	appos	32-17[231_0]
32-16	4216-4217	,	_	_	_	_
32-17	4218-4219	a	abstract[231]	giv[231]	_	_
32-18	4220-4226	HIF-1α	abstract|abstract[231]	giv|giv[231]	_	_
32-19	4227-4236	inhibitor	abstract[231]	giv[231]	_	_
32-20	4237-4238	,	_	_	_	_
32-21	4239-4249	supporting	_	_	_	_
32-22	4250-4253	the	abstract[232]	new[232]	_	_
32-23	4254-4264	conclusion	abstract[232]	new[232]	_	_
32-24	4265-4269	that	abstract[232]	new[232]	_	_
32-25	4270-4275	these	abstract[232]|abstract[233]	new[232]|giv[233]	coref	34-6[251_233]
32-26	4276-4283	effects	abstract[232]|abstract[233]	new[232]|giv[233]	_	_
32-27	4284-4288	were	abstract[232]	new[232]	_	_
32-28	4289-4297	mediated	abstract[232]	new[232]	_	_
32-29	4298-4305	through	abstract[232]	new[232]	_	_
32-30	4306-4309	the	abstract[232]|event[234]	new[232]|new[234]	_	_
32-31	4310-4320	activation	abstract[232]|event[234]	new[232]|new[234]	_	_
32-32	4321-4323	of	abstract[232]|event[234]	new[232]|new[234]	_	_
32-33	4324-4327	the	abstract[232]|event[234]|abstract[236]	new[232]|new[234]|giv[236]	coref	33-21[244_236]
32-34	4328-4331	HIF	abstract[232]|event[234]|abstract|abstract[236]	new[232]|new[234]|giv|giv[236]	coref	33-22
32-35	4332-4339	pathway	abstract[232]|event[234]|abstract[236]	new[232]|new[234]|giv[236]	_	_
32-36	4340-4341	.	_	_	_	_

#Text=These apparently contradictory studies suggest that , at least in the setting of vein graft NH , transient activation of the HIF pathway may protect the wall from hypoxia , whereas chronic activation may maintain the ongoing NH process .
33-1	4342-4347	These	abstract[237]	giv[237]	_	_
33-2	4348-4358	apparently	abstract[237]	giv[237]	_	_
33-3	4359-4372	contradictory	abstract[237]	giv[237]	_	_
33-4	4373-4380	studies	abstract[237]	giv[237]	_	_
33-5	4381-4388	suggest	_	_	_	_
33-6	4389-4393	that	_	_	_	_
33-7	4394-4395	,	_	_	_	_
33-8	4396-4398	at	_	_	_	_
33-9	4399-4404	least	_	_	_	_
33-10	4405-4407	in	_	_	_	_
33-11	4408-4411	the	abstract[238]	new[238]	_	_
33-12	4412-4419	setting	abstract[238]	new[238]	_	_
33-13	4420-4422	of	abstract[238]	new[238]	_	_
33-14	4423-4427	vein	abstract[238]|object|object[240]|abstract[241]	new[238]|giv|giv[240]|giv[241]	coref	33-38[0_241]
33-15	4428-4433	graft	abstract[238]|object[240]|abstract[241]	new[238]|giv[240]|giv[241]	_	_
33-16	4434-4436	NH	abstract[238]|abstract[241]	new[238]|giv[241]	_	_
33-17	4437-4438	,	_	_	_	_
33-18	4439-4448	transient	event[242]	new[242]	coref	33-32[247_242]
33-19	4449-4459	activation	event[242]	new[242]	_	_
33-20	4460-4462	of	event[242]	new[242]	_	_
33-21	4463-4466	the	event[242]|abstract[244]	new[242]|giv[244]	_	_
33-22	4467-4470	HIF	event[242]|abstract|abstract[244]	new[242]|giv|giv[244]	_	_
33-23	4471-4478	pathway	event[242]|abstract[244]	new[242]|giv[244]	_	_
33-24	4479-4482	may	_	_	_	_
33-25	4483-4490	protect	_	_	_	_
33-26	4491-4494	the	object[245]	giv[245]	coref	34-26[258_245]
33-27	4495-4499	wall	object[245]	giv[245]	_	_
33-28	4500-4504	from	_	_	_	_
33-29	4505-4512	hypoxia	abstract	giv	_	_
33-30	4513-4514	,	_	_	_	_
33-31	4515-4522	whereas	_	_	_	_
33-32	4523-4530	chronic	event[247]	giv[247]	_	_
33-33	4531-4541	activation	event[247]	giv[247]	_	_
33-34	4542-4545	may	_	_	_	_
33-35	4546-4554	maintain	_	_	_	_
33-36	4555-4558	the	abstract[249]	new[249]	_	_
33-37	4559-4566	ongoing	abstract[249]	new[249]	_	_
33-38	4567-4569	NH	abstract|abstract[249]	giv|new[249]	_	_
33-39	4570-4577	process	abstract[249]	new[249]	_	_
33-40	4578-4579	.	_	_	_	_

#Text=Carbon monoxide may also display vasoconstrictor effects depending on oxygen and metabolic homeostasis , including ROS production , highlighting the important role of metabolism in the vascular wall .
34-1	4580-4586	Carbon	substance[250]	giv[250]	_	_
34-2	4587-4595	monoxide	substance[250]	giv[250]	_	_
34-3	4596-4599	may	_	_	_	_
34-4	4600-4604	also	_	_	_	_
34-5	4605-4612	display	_	_	_	_
34-6	4613-4628	vasoconstrictor	abstract[251]	giv[251]	_	_
34-7	4629-4636	effects	abstract[251]	giv[251]	_	_
34-8	4637-4646	depending	abstract[251]	giv[251]	_	_
34-9	4647-4649	on	abstract[251]	giv[251]	_	_
34-10	4650-4656	oxygen	abstract[251]|substance|abstract[253]	giv[251]|giv|new[253]	_	_
34-11	4657-4660	and	abstract[251]|abstract[253]	giv[251]|new[253]	_	_
34-12	4661-4670	metabolic	abstract[251]|abstract[253]	giv[251]|new[253]	_	_
34-13	4671-4682	homeostasis	abstract[251]|abstract[253]	giv[251]|new[253]	_	_
34-14	4683-4684	,	abstract[251]|abstract[253]	giv[251]|new[253]	_	_
34-15	4685-4694	including	abstract[251]|abstract[253]	giv[251]|new[253]	_	_
34-16	4695-4698	ROS	abstract[251]|abstract[253]|substance|abstract[255]	giv[251]|new[253]|giv|new[255]	_	_
34-17	4699-4709	production	abstract[251]|abstract[253]|abstract[255]	giv[251]|new[253]|new[255]	_	_
34-18	4710-4711	,	_	_	_	_
34-19	4712-4724	highlighting	_	_	_	_
34-20	4725-4728	the	abstract[256]	new[256]	_	_
34-21	4729-4738	important	abstract[256]	new[256]	_	_
34-22	4739-4743	role	abstract[256]	new[256]	_	_
34-23	4744-4746	of	abstract[256]	new[256]	_	_
34-24	4747-4757	metabolism	abstract[256]|abstract	new[256]|giv	_	_
34-25	4758-4760	in	abstract[256]	new[256]	_	_
34-26	4761-4764	the	abstract[256]|object[258]	new[256]|giv[258]	_	_
34-27	4765-4773	vascular	abstract[256]|object[258]	new[256]|giv[258]	_	_
34-28	4774-4778	wall	abstract[256]|object[258]	new[256]|giv[258]	_	_
34-29	4779-4780	.	_	_	_	_
